<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39358920</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1742-481X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International wound journal</Title><ISOAbbreviation>Int Wound J</ISOAbbreviation></Journal><ArticleTitle>Recurrence rates after healing in patients with neuroischemic diabetic foot ulcers healed with and without sucrose octasulfate-impregnated dressings: A 1-year comparative prospective study.</ArticleTitle><Pagination><StartPage>e70028</StartPage><MedlinePgn>e70028</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70028</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/iwj.70028</ELocationID><Abstract><AbstractText>To compare recurrence rates after a 1-year follow-up period of healed neuroischemic diabetic foot ulcers after treatment with or without sucrose octasulfate impregnated dressing. A 1-year prospective study with two arms was conducted between April 2021 and April 2023 on 92 patients with healed neuroischemic diabetic foot ulcers. Patients were divided into two groups; the treatment group, that includes patients healed with a sucrose octasulfate-impregnated dressing, and the control group, which includes patients treated with other local treatments different from sucrose octasulfate-impregnated dressings. After healing, patients were prospectively followed up during 1-year and assessed monthly in the specialised outpatient clinics. The main outcome of the study was ulcer recurrence after wound healing within 1 year follow-up. Secondary outcomes were minor or major amputation and all causes of death. Fifty patients in the treatment group and 42 patients in the control group were included. Fourteen (28%) patients suffered from a reulceration event in the treatment group compared to 28 (66.7%) in the control group, p &lt; 0.001. Time to recurrence in the treatment group was 10 (16.26-2.75) and 11.50 (30.75-5.25) weeks in the control group, p = 0.464. There were no observed differences in the minor amputation rates between the two groups: 15.2% (n = 7) in the treatment group and 7.1% (n = 3) in the control group (p = 0.362). Major amputations and death outcomes were exclusively observed in the treatment group. Specifically, four major amputations (8.7%) in the treatment group were complications arising from recurring events complicated by infection during the SARS-CoV-2 period. Seven patients died due to complications not related with local therapy. The relative risk of recurrence was 20.18 times higher in the control group compared with those treated with octasulfate dressing (p &lt; 0.001). Treatment with sucrose octasulfate-impregnated dressings can decrease recurrence rates of neuroischaemic diabetic foot ulcers more effectively than neutral dressings. Besides, it may enhance the foot's clinical properties in patients with poor microcirculation, which could aid in preventing future recurrences.</AbstractText><CopyrightInformation>© 2024 The Author(s). International Wound Journal published by Medicalhelplines.com Inc and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lázaro-Martínez</LastName><ForeName>José Luis</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-6110-0265</Identifier><AffiliationInfo><Affiliation>Diabetic Foot Unit, Clínica Universitaria de Podología, Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Madrid</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Diabetic Foot Unit, Clínica Universitaria de Podología, Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohbot</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Global Medical Affairs Director, Laboratoires URGO, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Moral</LastName><ForeName>Mateo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7342-059X</Identifier><AffiliationInfo><Affiliation>Diabetic Foot Unit, Clínica Universitaria de Podología, Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molines-Barroso</LastName><ForeName>Raúl J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Diabetic Foot Unit, Clínica Universitaria de Podología, Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Álvarez</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Diabetic Foot Unit, Clínica Universitaria de Podología, Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Wound J</MedlineTA><NlmUniqueID>101230907</NlmUniqueID><ISSNLinking>1742-4801</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>57-50-1</RegistryNumber><NameOfSubstance UI="D013395">Sucrose</NameOfSubstance></Chemical><Chemical><RegistryNumber>P7V86EYZ5L</RegistryNumber><NameOfSubstance UI="C053081">sucrose octasulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017719" MajorTopicYN="Y">Diabetic Foot</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="Y">Wound Healing</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="Y">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001458" MajorTopicYN="Y">Bandages</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013395" MajorTopicYN="Y">Sucrose</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000671" MajorTopicYN="N">Amputation, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diabetic foot</Keyword><Keyword MajorTopicYN="N">microcirculation</Keyword><Keyword MajorTopicYN="N">neuroischaemic diabetic foot ulcer</Keyword><Keyword MajorTopicYN="N">recurrence</Keyword><Keyword MajorTopicYN="N">sucrose octasulfate dressing</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39358920</ArticleId><ArticleId IdType="pmc">PMC11447856</ArticleId><ArticleId IdType="doi">10.1111/iwj.70028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armstrong DG, Cohen K, Courric S, Bharara M, Marston W. Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol. 2011;5(6):1591‐1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262731</ArticleId><ArticleId IdType="pubmed">22226282</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulton AJM, Armstrong DG, Londahl M, et al. New Evidence‐Based Therapies for Complex Diabetic Foot Wounds. American Diabetes Association; 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35763580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Vilorio NC, Dhatariya K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2024;40:e3644.</Citation><ArticleIdList><ArticleId IdType="pubmed">37232034</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmonds M, Lazaro‐Martinez JL, Alfayate‐Garcia JM, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (explorer): an international, multicentre, double‐blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018;6(3):186‐196.</Citation><ArticleIdList><ArticleId IdType="pubmed">29275068</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institute for Health and Care Excellence
. UrgoStart NICE, for treating DFUs and leg ulcers. Medical technologies guidance [MTG42]. Accessed April 4, 2023. https://www.nice.org.uk/guidance/mtg42
</Citation></Reference><Reference><Citation>Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367‐2375.</Citation><ArticleIdList><ArticleId IdType="pubmed">28614678</ArticleId></ArticleIdList></Reference><Reference><Citation>Akturk A, van Netten JJ, Scheer R, Vermeer M, van Baal JG. Ulcer‐free survival days and ulcer healing in patients with diabetic foot ulcers: a prospective cohort study. Int Wound J. 2019;16(6):1365‐1372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7948914</ArticleId><ArticleId IdType="pubmed">31429183</ArticleId></ArticleIdList></Reference><Reference><Citation>Westphal C, Neame IM, Harrison JC, Bower VM, Gurr JM. A diabetic foot ulcer pilot study: does silicone gel sheeting reduce the incidence of reulceration? J Am Podiatr Med Assoc. 2011;101(2):116‐123.</Citation><ArticleIdList><ArticleId IdType="pubmed">21406694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaro‐Martinez JL, Aragon‐Sanchez J, Alvaro‐Afonso FJ, Garcia‐Morales E, Garcia‐Alvarez Y, Molines‐Barroso RJ. The best way to reduce reulcerations: if you understand biomechanics of the diabetic foot, you can do it. Int J Low Extrem Wounds. 2014;13(4):294‐319.</Citation><ArticleIdList><ArticleId IdType="pubmed">25256280</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubsky M, Jirkovska A, Bem R, et al. Risk factors for recurrence of diabetic foot ulcers: prospective follow‐up analysis in the Eurodiale subgroup. Int Wound J. 2013;10(5):555‐561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7950559</ArticleId><ArticleId IdType="pubmed">22712631</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Schaper N, Rayman G. Microangiopathy: is it relevant to wound healing in diabetic foot disease? Diabetes Metab Res Rev. 2020;36(Suppl 1):e3244.</Citation><ArticleIdList><ArticleId IdType="pubmed">31845461</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CY, Cheing GL. Microvascular dysfunction in diabetic foot disease and ulceration. Diabetes Metab Res Rev. 2009;25(7):604‐614.</Citation><ArticleIdList><ArticleId IdType="pubmed">19681035</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan ST, Baker NR, Carrington AL, Rayman G. Comparative roles of microvascular and nerve function in foot ulceration in type 2 diabetes. Diabetes Care. 2004;27(6):1343‐1348.</Citation><ArticleIdList><ArticleId IdType="pubmed">15161786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaro‐Martinez JL, Lopez‐Moral M, Garcia‐Alamino JM, Bohbot S, Sanz‐Corbalan I, Garcia‐Alvarez Y. Evolution of the TcPO2 values following hyperoxygenated fatty acids emulsion application in patients with diabetic foot disease: results of a clinical trial. J Wound Care. 2021;30(1):74‐79.</Citation><ArticleIdList><ArticleId IdType="pubmed">33439078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffini I, Belcaro G, Cesarone MR, et al. Evaluation of the local effects of vitamin E (E‐mousse) on free radicals in diabetic microangiopathy: a randomized, controlled trial. Angiology. 2003;54(4):415‐421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12934761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalani M, Silveira A, Blomback M, et al. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res. 2007;120(5):653‐661.</Citation><ArticleIdList><ArticleId IdType="pubmed">17275886</ArticleId></ArticleIdList></Reference><Reference><Citation>Belcaro G, Cesarone MR, Errichi BM, et al. Diabetic ulcers: microcirculatory improvement and faster healing with pycnogenol. Clin Appl Thromb Hemost. 2006;12(3):318‐323.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959685</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon KC, Chung HY, Han SK, Jeong SH, Dhong ES. Possibility of injecting adipose‐derived stromal vascular fraction cells to accelerate microcirculation in ischemic diabetic feet: a pilot study. Int J Stem Cells. 2019;12(1):107‐113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6457712</ArticleId><ArticleId IdType="pubmed">30836733</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadee AN, Aref MHF, Nassar AA, Aboughaleb IH, Fahmy SM. The influence of low‐ intensity laser irradiation versus hyperbaric oxygen therapy on transcutaneous oxygen tension in chronic diabetic foot ulcers: a controlled randomized trial. J Diabetes Metab Disord. 2021;20(2):1489‐1497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8630261</ArticleId><ArticleId IdType="pubmed">34900800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaro‐Martinez JL, Garcia‐Madrid M, Garcia‐Alamino JM, Bohbot S, Garcia‐Klepzig JL, Garcia‐Alvarez Y. Increasing transcutaneous oxygen pressure in patients with neuroischemic diabetic foot ulcers treated with a sucrose octasulfate dressing: a pilot study. Int J Low Extrem Wounds. 2022;21:450‐456.</Citation><ArticleIdList><ArticleId IdType="pubmed">32856522</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaro‐Martinez JL, Garcia‐Madrid M, Bohbot S, Lopez‐Moral M, Alvaro‐Afonso FJ, Garcia‐Alvarez Y. Microcirculation improvement in diabetic foot patients after treatment with sucrose octasulfate‐impregnated dressings. J Clin Med. 2023;12(3):1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9918046</ArticleId><ArticleId IdType="pubmed">36769685</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Netten JJ, Raspovic A, Lavery LA, et al. Prevention of foot ulcers in persons with diabetes at risk of ulceration: a systematic review and meta‐analysis. Diabetes Metab Res Rev. 2023;40:e3652.</Citation><ArticleIdList><ArticleId IdType="pubmed">37243880</ArticleId></ArticleIdList></Reference><Reference><Citation>Bus SA, Sacco ICN, Monteiro‐Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2024;40:e3651.</Citation><ArticleIdList><ArticleId IdType="pubmed">37302121</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191‐2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez‐Moral M, Lazaro‐Martinez JL, Garcia‐Morales E, Garcia‐Alvarez Y, Alvaro‐Afonso FJ, Molines‐Barroso RJ. Clinical efficacy of therapeutic footwear with a rigid rocker sole in the prevention of recurrence in patients with diabetes mellitus and diabetic polineuropathy: a randomized clinical trial. PLoS One. 2019;14(7):e0219537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623964</ArticleId><ArticleId IdType="pubmed">31295292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwaferink JBJ, Custers W, Paardekooper I, Berendsen HA, Bus SA. Optimizing footwear for the diabetic foot: data‐driven custom‐made footwear concepts and their effect on pressure relief to prevent diabetic foot ulceration. PLoS One. 2020;15(4):e0224010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179916</ArticleId><ArticleId IdType="pubmed">32324739</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitridge R, Chuter V, Mills J, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer. Diabetes Metab Res Rev. 2023;40:e3686.</Citation><ArticleIdList><ArticleId IdType="pubmed">37726988</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaper NC, van Netten JJ, Apelqvist J, et al. Practical guidelines on the prevention and management of diabetes‐related foot disease (IWGDF 2023 update). Diabetes Metab Res Rev. 2024;40:e3657.</Citation><ArticleIdList><ArticleId IdType="pubmed">37243927</ArticleId></ArticleIdList></Reference><Reference><Citation>Molines‐Barroso RJ, Lazaro‐Martinez JL, Aragon‐Sanchez J, Garcia‐Morales E, Beneit‐Montesinos JV, Alvaro‐Afonso FJ. Analysis of transfer lesions in patients who underwent surgery for diabetic foot ulcers located on the plantar aspect of the metatarsal heads. Diabet Med. 2013;30(8):973‐976.</Citation><ArticleIdList><ArticleId IdType="pubmed">23600614</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu XL, Ding H, Miao WW, Mao CX, Zhan MQ, Chen HL. Global recurrence rates in diabetic foot ulcers: a systematic review and meta‐analysis. Diabetes Metab Res Rev. 2019;35(6):e3160.</Citation><ArticleIdList><ArticleId IdType="pubmed">30916434</ArticleId></ArticleIdList></Reference><Reference><Citation>Oropallo AR, Serena TE, Armstrong DG, Niederauer MQ. Molecular biomarkers of oxygen therapy in patients with diabetic foot ulcers. Biomolecules. 2021;11(7):925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8301753</ArticleId><ArticleId IdType="pubmed">34206433</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavery LA, Peters EJ, Armstrong DG. What are the most effective interventions in preventing diabetic foot ulcers? Int Wound J. 2008;5(3):425‐433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7951312</ArticleId><ArticleId IdType="pubmed">18593392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavery LA, Higgins KR, Lanctot DR, et al. Preventing diabetic foot ulcer recurrence in high‐risk patients: use of temperature monitoring as a self‐assessment tool. Diabetes Care. 2007;30(1):14‐20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192326</ArticleId></ArticleIdList></Reference><Reference><Citation>van Netten JJ, Price PE, Lavery LA, et al. Prevention of foot ulcers in the at‐risk patient with diabetes: a systematic review. Diabetes Metab Res Rev. 2016;32(Suppl 1):84‐98.</Citation><ArticleIdList><ArticleId IdType="pubmed">26340966</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch K, Chantelau E. Effectiveness of a new brand of stock ‘diabetic’ shoes to protect against diabetic foot ulcer relapse. A prospective cohort study. Diabet Med. 2003;20(8):665‐669.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873296</ArticleId></ArticleIdList></Reference><Reference><Citation>Uccioli L, Faglia E, Monticone G, et al. Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care. 1995;18(10):1376‐1378.</Citation><ArticleIdList><ArticleId IdType="pubmed">8721941</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Ying G, Jing O, et al. Influencing factors for the recurrence of diabetic foot ulcers: a meta‐analysis. Int Wound J. 2023;20(5):1762‐1775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10088840</ArticleId><ArticleId IdType="pubmed">36385501</ArticleId></ArticleIdList></Reference><Reference><Citation>Giurato L, Andrea P, Meloni M, Pecchioli C, D'Ambrogi E, Uccioli L. Risk factors for ulcer recurrence in diabetic patients managed by an integrated foot care protocol. Int J Low Extrem Wounds. 2023;15347346231191583.</Citation><ArticleIdList><ArticleId IdType="pubmed">37654086</ArticleId></ArticleIdList></Reference><Reference><Citation>Aragon‐Sanchez J, Viquez‐Molina G, Lopez‐Valverde ME, Rojas‐Bonilla JM, Murillo‐Vargas C. Conservative surgery for diabetic foot osteomyelitis is not associated with longer survival time without recurrence of foot ulcer when compared with amputation. Int J Low Extrem Wounds. 2023;22(2):328‐331.</Citation><ArticleIdList><ArticleId IdType="pubmed">33890818</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia‐Madrid M, Garcia‐Alvarez Y, Sanz‐Corbalan I, Alvaro‐Afonso FJ, Lopez‐Moral M, Lazaro‐Martinez JL. Predictive value of forefoot plantar pressure to predict reulceration in patients at high risk. Diabetes Res Clin Pract. 2022;189:109976.</Citation><ArticleIdList><ArticleId IdType="pubmed">35772587</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaro‐Martinez JL, Sanchez‐Rios JP, Garcia‐Morales E, Cecilia‐Matilla A, Segovia‐Gomez T. Increased transcutaneous oxygen tension in the skin dorsum over the foot in patients with diabetic foot disease in response to the topical use of an emulsion of hyperoxygenated fatty acids. Int J Low Extrem Wounds. 2009;8(4):187‐193.</Citation><ArticleIdList><ArticleId IdType="pubmed">19825855</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez‐Reyes G, Garcia‐Ulloa AC, Hernandez‐Jimenez S, et al. Effect of whole‐body vibration training on transcutaneous oxygen levels of the foot in patients with type 2 diabetes: a randomized controlled trial. J Biomech. 2022;139:110871.</Citation><ArticleIdList><ArticleId IdType="pubmed">34839962</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindl A, Schindl M, Schon H, Knobler R, Havelec L, Schindl L. Low‐intensity laser irradiation improves skin circulation in patients with diabetic microangiopathy. Diabetes Care. 1998;21(4):580‐584.</Citation><ArticleIdList><ArticleId IdType="pubmed">9571346</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Xiao Z, Chen L, et al. Cilostazol can increase skin oxygen supply assessed by transcutaneous oxygen pressure measurement in type 2 diabetes with lower limb ischemic disease: a randomized trial. J Wound Ostomy Continence Nurs. 2016;43(3):254‐259.</Citation><ArticleIdList><ArticleId IdType="pubmed">26938333</ArticleId></ArticleIdList></Reference><Reference><Citation>Papa G, Spazzapan L, Pangos M, Delpin A, Arnez ZM. Compared to coverage by STSG grafts only reconstruction by the dermal substitute Integra(R) plus STSG increases TcPO2 values in diabetic feet at 3 and 6 months after reconstruction*. G Chir. 2014;35(5–6):141‐145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321518</ArticleId><ArticleId IdType="pubmed">24979107</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire JB. Pressure redistribution strategies for the diabetic or at‐risk foot: part II. Adv Skin Wound Care. 2006;19(5):270‐277; quiz 7–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732073</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder RJ, Lanier KK. Offloading difficult wounds and conditions in diabetic patient. Ostomy Wound Manage. 2002;48(1):22‐28, 30, 32–35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15382389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundó M, Vlacho B, Llussà J, et al. Prediction of outcomes in subjects with type 2 diabetes and diabetic foot ulcers in Catalonian primary care centers: a multicenter observational study. J Foot Ankle Res. 2023;16(1):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9972716</ArticleId><ArticleId IdType="pubmed">36849888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann‐Boyce J, Highton P, Rees K, et al. The impact of the COVID‐19 pandemic and associated disruptions in healthcare provision on clinical outcomes in people with diabetes: a systematic review. Lancet Diabetes Endocrinol. 2024;12(2):132‐148.</Citation><ArticleIdList><ArticleId IdType="pubmed">38272607</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain SN, Choi JY, Cooper B, Renwick B, Mohamed MM, Makris SA. Long‐term impact of COVID‐19 related disruption of NHS elective services on emergency major lower limb amputations. Ann Vasc Surg. 2024;102:84‐91.</Citation><ArticleIdList><ArticleId IdType="pubmed">38280485</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>